It seems that opposition against anti-aging medicine may be slowly starting to crumble. For example, Lifespan.io’s current crowdfunding campaign is going extremely well, and journalists begin to talk about senolytics in positive terms, without any predictions of doom and gloom resulting from these upcoming drugs. Make no mistake—the pro-aging trance is still alive and well; for each journalist who puts time and effort into actually understanding senolytics and the health benefits that they are expected to bring to older people, there’s probably five who show little to no knowledge of the subject and rage against unspecified “immortality” technology and related impending catastrophes. This should tell us something about the kind of understanding they have of what they criticize—or how badly they need a clickbait piece to bring in visitors.

Today, the pro-aging trance is something that only rejuvenation advocates are aware of and battle against, but maybe, fifty years from now, it will be an interesting phenomenon of the past for psychologists to figure out. Maybe, on the YouTube of 2068, there will be videos making fun of it in pretty much the same way that some people today make fun of the old belief that hysteria was caused by stray uteruses wandering around women’s bodies.

The pro-aging trance is rather interesting indeed, as people who are subject to it tend to commit fallacies that they would never commit in other contexts. A very good example of this is the objection to inequality of access: this reasoning assumes that rejuvenation would not be available to everyone who needs it, for economical, political, or whatever reasons; understandably, this is perceived as a profound injustice, which pushes a fair number of people to make a leap and conclude that the best way to avoid this injustice is to never develop rejuvenation to begin with.

Drugs that target multiple aging pathways at once significantly extend the healthspan and lifespan of nematodes.

In a paper published in Developmental Cell, scientists from Yale University have demonstrated how targeting multiple pathways related to aging with different drug combinations can slow aging down and extend healthy lifespan in C. elegans [1].

Abstract

There is growing interest in pharmacological interventions directly targeting the aging process. Pharmacological interventions against aging should be efficacious when started in adults and, ideally, repurpose existing drugs. We show that dramatic lifespan extension can be achieved by targeting multiple, evolutionarily conserved aging pathways and mechanisms using drug combinations. Using this approach in C. elegans, we were able to slow aging and significantly extend healthy lifespan. To identify the mechanism of these drug synergies, we applied transcriptomics and lipidomics analysis. We found that drug interactions involved the TGF-b pathway and recruited genes related with IGF signaling. daf-2, daf-7, and sbp-1 interact upstream of changes in lipid metabolism, resulting in increased monounsaturated fatty acid content and this is required for healthy lifespan extension.

The brilliant Prof Judith Campisi from Buck Institute on Aging on senescence, senolytics, healthspan and more, a new interview.

Anti-aging pioneer Judith Campisi explains how a recent breakthrough could ward off age-related disease.

A study suggests cardiorespiratory fitness is linked to a longer life, suggesting no exercise is worse for health than smoking or diabetes.

Judith Campisi as a speaker for the 2019 Undoing Aging Conference.

At Lawrence Berkeley National Laboratory and at the Buck Institute for Research on Aging, Dr. Judith Campisi established a broad program to understand the relationship between aging and age-related disease.

Judith Campisi says: “Aging research has entered an era of unprecedented hope for interventions that can prevent, delay and, in some cases, reverse much of the functional decline that is a hallmark of aging. There is still a lot of research to be done! I am delighted to be among the speakers at Undoing Aging 2019, where I will discuss the opportunities and challenges of our recent research.”

“Judy has been a towering figure in the field of senescent cells for decades; among other things she pioneered the idea that senescent cells could be actively toxic to their environment and the discovery that cell senescence has a beneficial physiological role in wound healing. She was also one of the first senior gerontologists to appreciate the merits of the SENS approach when I first proposed it in 2000, and her support for it and us ever since has been of incalculable benefit in helping it achieve the mainstream status it enjoys today.” says Aubrey de Grey.